We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cyprotex | CRX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 160.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 160.50 | 160.50 |
| Top Posts |
|---|
Posted at 03/7/2017 07:40 by buywell3 LiDCO had a good lift on friday , has any ex CRX holder joined the party ?I have been doing some more digging , and like what I am finding out check out todays LID post by buywell |
Posted at 23/6/2017 08:21 by buywell3 It was a long and bumpy ride but CRX got there in the endI have to say trying to find a small cap company in the Pharma Biotech sector that is making profits, has no debt and has cash to aid a sales push is next to impossible, especially at a decent entry point. I don't like to follow herds, where valuations have become stretched. However Husbod , since you stayed the course here this post is for you, and I still don't like resource stocks I might add. This new product LiDCOunity v2 seems to have the potential to gain a decent market share in the USA. Edwards is the local USA based market leader , and has been for years now But clinical evidence has put Lidco ahead of that product and two other competitors That evidence was a few years ago on an older Lidco model (still being sold), but this new model with the same algorithm (IP protected) at its core , but with many new enhanced features could now prove pivotal in gaining increased USA sales together with the much increased number of USA sales staff. Over the next 3 years I expect Lidco to accelerate its USA presence with more USA selected states being targeted for sales by the addition of more sales staff. Plus ROW sales to continue to increase particularly in Asia. Lidco has a major market share within the UK NHS in its area of expertise with around 55%, this new product should help it maintain that lead. However it is in the USA where the company will make the most money now as the new CEO has identified and built his well thought out sales strategy upon. This guy Sassone , is an experienced sales specialist, he is what the company lacked ; now that there is no debt and over £4M cash to allow a long needed and targeted sales drive , primarily into the USA and secondarily into the ROW , turnover and bigger profits should in my opinion follow. The strategy report which starts on page 5 in the link below is one of the most concise and well detailed reports I have ever read in a small cap company , The recent change of chart shape over the last year supports my view, the market likes what it is seeing and hearing from Sassone. He has been incentivised via share options on a sliding scale re increased share price which includes him benefiting if Lidco should be bought out at a higher price within the sliding scale band.see page 19 I think Edwards will buy Lidco within 3 years. |
Posted at 13/12/2016 10:11 by husbod Scheme Court hearing today, suspension of shares tomorrow and cancellation of shares on Thursday if everything goes to plan. So our lovely little UK company will cease to exist in less than 72 hours.I thought buywell might pop back in with his final thoughts and maybe give us an idea on any other tiddlers in this sector that could prove to be the next CRX. Not sure when we receive our loot though - should it be in our accounts on Thursday I wonder? |
Posted at 21/11/2016 09:53 by p1nkfish To anyone sitting on a profit in CRX I suspect you will have chance to allocate the cash realised is an efficient fashion elsewhere in he not too distant future. Cash could be king again for a while.Looking at the current market I am coming round to the idea that the sale of CRX is the best outcome. They would need more cash for the move and there is a bitter wind about to blow across all the markets that would hit CRX too. A shift down in valuations would be no surprise so the timing of this exit may be fortuotous - looking on the bright side - liberating cash. Keep an eye on Evotecs valuation as that will be telling as to what might have happened to CRX. Not immediately but in the next 12-18 months. CRX, a great British company but not immune from what may be about to hit the markets. You could always but into Evotec in future. |
Posted at 18/11/2016 17:49 by tiptop22 Evotec clearly see the real opportunity!ABOUT CYPROTEX Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including its proprietary CellCiphr(R) toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe(R) PK, chemPK(TM), chemTarget, chemTox and DDI-Fusion and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com. |
Posted at 18/11/2016 17:44 by tiptop22 Having given the offer some serious thoughts,I have sent in my proxy and have voted against,I think that it is in the best interests of the company its employees,their customers that CRX remains an independent British Company,The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Evotec will pay approximately £ 55.36 m (EUR 62.00 m; £/EUR exchange rate of 1.12) in cash for the acquisition of all 26.1 million issued and to be issued Cyprotex shares and the funding of all existing company debt. Evotec The offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of the past 30 trading days at AIM. The offer is intended to be implemented by a scheme of arrangement regulated by the UK takeover code, with already >50% shares secured irrevocable. The acquisition will add to Evotec's revenues and be accretive to Evotec's 2017 EBITDA. Cyprotex is the world's largest contract research organisation specialising in pre-clinical ADME-Tox and DMPK serving the Pharmaceutical, Chemical, Agrochemical and Cosmetics markets. Cyprotex, headquartered in the UK, was founded in 1999 and is publicly traded on AIM (CRX). It has 136 employees working from sites at Macclesfield and Alderley Park, both of which are located near Manchester in the UK, and at Watertown, MA, and Kalamazoo, MI, in the USA. With more than 1,500 partners, Cyprotex has a very strong customer network. Cyprotex reported H1 2016 revenues of £ 8.73 m (EUR 9.78 m) (H1 2015: £ 6.93 m (EUR 7.76 m)) with an underlying EBITDA of £ 2.34 m (EUR 2.62 m) (H1 2015: £ 1.10 m (EUR 1.23 m)). Clearly it is on the cusp of real growth both in revenue and profits. I urge all PI's to vote against the motion. It is also my firm believe that an American buyer would be a more appropriate acquirer,the real opportunities for the technology and services that have been developed over the last 14 years or so are in the UK and the US. Surely eventually one of the big US CRO's would pay more than a 9.4% premium, if you vote against the motion CRX will attract the attentions of other suitors in due course willing to pay more than 9.4% premium, |
Posted at 03/10/2016 08:38 by bahiflyer Brokers are usually paid by the company they work for to give them a pep up now and again unless you are a very large Co with institutional interest.CRX isn't in need of artificial inflation and isn't quite big enough for insti following.....not yet. Salty, if you go back about a year on the other BB thread there was some really good research put up by Buywell3, also the CRX blog on their web site gives a good insight as to who they work for, what they do and the legislation they lead the way in Cheers ATB |
Posted at 29/9/2016 13:46 by saltaire111 I don't really understand the science in the work that crx does but was talking to a colleague who thinks that the new CEO of GSK may be good news for crx. He said this was because she realises the retail opportunity in reduced animal testing on products and that CRX is the market leader in eliminating animal testing for cosmetics. Could anyone more qualified shed any light on this? I can't see anything about the elimination of animal testing on the crx website.Thanks Salty |
Posted at 24/7/2016 18:24 by husbod Good to have your thoughts B.Any idea if the guys at the top of CRX and SBS know each other? I know absolutely nothing about SBS and do not have the time to research it but one obvious implication of your post would be the benefit of a friendly merger of the two companies or a take-over by CRX of SBS. Those on this bb who know SBS far better than me might well say that this is an absurd idea and that any such relationship is the last thing CRX should consider. Any thoughts guys? 200p seems a bit of a modest take out price B. |
Posted at 23/7/2016 08:51 by deadly FYI:buywell2 23 Jul'16 - 01:18 - 37 of 37 0 0 edit I suggest you all read the latest annual report on the company website There is a hidden nugget within which my take means Cyprotex have a decent large contract is now underway with a large Pharma , I know which one but it would not be prudent to say which one it was . These BIG Pharmas do NOT want their business aired in public so have told Cyprotex to stay quiet ie no RNS My gut tells me a predator/s are now looking at both SBS and CRX Current exchange rate moves have made a purchase now cheaper for those outside the UK One of them might want part of SBS but not the whole Likewise with CRX One of them might want CRX with part of SBS as an add on to include molecular diagnostics and DNA sequencing to CRX services which have expanded at a very fast clip of late. What we must hope for is that a move is not made before the interims are released as they will make a buyout price in excess of 200p possible in 2017 What I also hope will happen is that the BIG Pharma will be the one to buy CRX when another foreign offer is made , I also think I know who that will be. My take is that the BIG Pharma might even want BOTH Cyprotex and Source Bioscience to become one company as such a combination would enhance their Personalized Medicine aspirations plus gain a better foothold in the UK and NHS market (via SBS) So on the whole my hopes and dreams for the 2 companies remain What price a CRX/SBS combine would be would be interesting to ponder There would be savings and cross selling benefits to be made A profit of 10M within 3 years from such a combine as work from the USA looks set to rocket due to recent EPA workload and USA chemical testing law changes meaning more Toxicology and Endocrine Disruptor testing looks undemanding A buyout price for such a business then would be in the region of 250 Million pounds Can the BODS of both companies see the logic ? Can the major shareholders make them if the don't ? We will soon find out |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
